Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 4
2016 2
2017 3
2018 6
2020 5
2021 5
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O. Ghesquières H, et al. Among authors: kanoun s. Blood. 2024 Mar 14;143(11):983-995. doi: 10.1182/blood.2023021564. Blood. 2024. PMID: 37979133 Clinical Trial.
Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
Carlier T, Frécon G, Mateus D, Rizkallah M, Kraeber-Bodéré F, Kanoun S, Blanc-Durand P, Itti E, Le Gouill S, Casasnovas RO, Bodet-Milin C, Bailly C. Carlier T, et al. Among authors: kanoun s. J Nucl Med. 2024 Jan 2;65(1):156-162. doi: 10.2967/jnumed.123.265872. J Nucl Med. 2024. PMID: 37945379
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. Al Tabaa Y, et al. Among authors: kanoun s. Blood Adv. 2023 Jul 25;7(14):3735-3738. doi: 10.1182/bloodadvances.2023009911. Blood Adv. 2023. PMID: 37067945 Free PMC article. No abstract available.
Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.
Chevreux S, de Barros S, Laurent C, Durand A, Delpierre C, Robert P, Joubert C, Griolet S, Kanoun S, Bastie JN, Casasnovas RO, Rossi C. Chevreux S, et al. Among authors: kanoun s. Cancers (Basel). 2022 Dec 22;15(1):53. doi: 10.3390/cancers15010053. Cancers (Basel). 2022. PMID: 36612050 Free PMC article.
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac AC, Moatti H, Fornecker LM, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau AS, Casasnova RO. Rossi C, et al. Among authors: kanoun s. Haematologica. 2022 Dec 1;107(12):2897-2904. doi: 10.3324/haematol.2021.280004. Haematologica. 2022. PMID: 35638548 Free PMC article.
"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.
Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M. Lapierre L, et al. Among authors: kanoun s. Hematol Oncol. 2022 Oct;40(4):805-808. doi: 10.1002/hon.2985. Epub 2022 Mar 8. Hematol Oncol. 2022. PMID: 35246868 No abstract available.
Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.
Revailler W, Cottereau AS, Rossi C, Noyelle R, Trouillard T, Morschhauser F, Casasnovas O, Thieblemont C, Gouill SL, André M, Ghesquieres H, Ricci R, Meignan M, Kanoun S. Revailler W, et al. Among authors: kanoun s. Diagnostics (Basel). 2022 Feb 6;12(2):417. doi: 10.3390/diagnostics12020417. Diagnostics (Basel). 2022. PMID: 35204515 Free PMC article.
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, Sibon D, Antoine C, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoullas A, Filliatre-Clement L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Rocquet M, Raus N, Burroni B, Rubio MT, Bouscary D, Quittet P, Casasnovas RO, Brice P, Ghesquieres H, Tamburini J, Deau B. Marouf A, et al. Among authors: kanoun s. Haematologica. 2022 Jul 1;107(7):1681-1686. doi: 10.3324/haematol.2021.279564. Haematologica. 2022. PMID: 34965701 Free PMC article. No abstract available.
34 results